Clinical Trials Directory

Trials / Completed

CompletedNCT01802723

Dose Ranging Study

A Dose Ranging Study of the Safety and Efficacy of LIPO-202 Healthy Patients With Subcutaneous Fat in the Periumbilical Area

Status
Completed
Phase
Phase 2
Study type
Interventional
Enrollment
472 (actual)
Sponsor
Neothetics, Inc · Industry
Sex
All
Age
18 Years
Healthy volunteers
Accepted

Summary

Dose Ranging Study

Conditions

Interventions

TypeNameDescription
DRUGDrug: salmeterol xinafoate
DRUGDrug: Placebo

Timeline

Start date
2013-02-01
Primary completion
2013-06-01
Completion
2013-10-01
First posted
2013-03-01
Last updated
2015-03-26

Locations

22 sites across 1 country: United States

Source: ClinicalTrials.gov record NCT01802723. Inclusion in this directory is not an endorsement.